Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford BioMedica PLC

www.oxfordbiomedica.co.uk

Latest From Oxford BioMedica PLC

Oxford Biomedica, Microsoft Pact Aims At Better, Cheaper Lentiviral Vectors

Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.

Artificial Intelligence Business Strategies

Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy

Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.

Research & Development Neurology

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

Respiratory Research and Development Strategies

Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade

Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.

Respiratory Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Services
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford BioMedica PLC
  • Senior Management
  • John Dawson, CEO
    Stuart Paynter, CFO
    Jason Slingsby, CBO
    Kyriacos Mitrophanous, CSO
    James Miskin, CTO
    Nick Page, COO
    Lisa Giles, Chief Project & Dev Officer
  • Contact Info
  • Oxford BioMedica PLC
    Phone: (44) 1865 783 000
    Windrush Court
    Transport Way
    Oxford, OX4 6LT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register